Related references
Note: Only part of the references are listed.Prevalence of Vitiligo Among Adults in the United States
Kavita Gandhi et al.
JAMA DERMATOLOGY (2022)
33300 Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes repigmentation of stable lesions in patients with active nonsegmental vitiligo: Results from a phase 2b, randomized, placebo-controlled, dose-ranging study
Yuji Yamaguchi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
An update on Vitiligo pathogenesis
Julien Seneschal et al.
PIGMENT CELL & MELANOMA RESEARCH (2021)
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Fei Qi et al.
FRONTIERS IN IMMUNOLOGY (2021)
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Brett King et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma
Aleksey K. Molodtsov et al.
IMMUNITY (2021)
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
Andrew Blauvelt et al.
JAMA DERMATOLOGY (2021)
Targeting ITK signaling for T cell-mediated diseases
Samuel Weeks et al.
ISCIENCE (2021)
Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study
W. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2021)
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
E. L. Simpson et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
The Role of TRM Cells in the Pathogenesis of Vitiligo-A Review of the Current State-Of-The-Art
Alicja Fraczek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The enigma and challenges of vitiligo pathophysiology and treatment
Zalfa A. Abdel-Malek et al.
PIGMENT CELL & MELANOMA RESEARCH (2020)
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Michael F. Robinson et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
David Rosmarin et al.
LANCET (2020)
Vitiligo, From Physiopathology to Emerging Treatments: A Review
Laure Migayron et al.
DERMATOLOGY AND THERAPY (2020)
Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT
Jonathan M. Batchelor et al.
HEALTH TECHNOLOGY ASSESSMENT (2020)
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor
Hua Xu et al.
ACS CHEMICAL BIOLOGY (2019)
The Role of Memory CD8+ T Cells in Vitiligo
Rebecca L. Riding et al.
JOURNAL OF IMMUNOLOGY (2019)
Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo
Jillian M. Richmond et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose. Narrowband UV-B Phototherapy
Sa Rang Kim et al.
JAMA DERMATOLOGY (2018)
CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin
Stanley Cheuk et al.
IMMUNITY (2017)
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Lucy Y. Liu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
JAK inhibitors in dermatology: The promise of a new drug class
William Damsky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Phototherapy for Vitiligo A Systematic Review and Meta-analysis
Jung Min Bae et al.
JAMA DERMATOLOGY (2017)
Vitiligo: An Update on Pathophysiology and Treatment Options
Reinhart Speeckaert et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Quality of Life, Burden of Disease, Co-morbidities, and Systemic Effects in Vitiligo Patients
Nada Elbuluk et al.
DERMATOLOGIC CLINICS (2017)
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
John E. Harris et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Tofacitinib Citrate for the Treatment of Vitiligo A Pathogenesis-Directed Therapy
Brittany G. Craiglow et al.
JAMA DERMATOLOGY (2015)
Vitiligo
Mauro Picardo et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Vitiligo nonsurgical treatment: a review of latest treatment researches
Yanfei Zhang et al.
DERMATOLOGIC THERAPY (2014)
Melanocytes and Their Diseases
Yuji Yamaguchi et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
A review of the worldwide prevalence of vitiligo in children/adolescents and adults
Christian Krueger et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2012)
Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference
K. Ezzedine et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Vitiligo: what general physicians need to know
David J. Gawkrodger
CLINICAL MEDICINE (2009)
Share Paper
